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Summary Survival in squamous cell carcinoma of the head and neck (HNSCC) was compared with overexpression and mutation of the p53
gene. Archival tissue from 77 tumours was analysed for protein expression using immunohistochemistry (IHC) with the monoclonal antibody
Do-7, and for the presence of mutation in exons 5-8 using single-stranded conformation polymorphism (SSCP), followed by DNA sequencing
in SSCP-positive cases. p53 expression was scored as high (>70% nuclei stained) in 25 (32%) tumours, as intermediate (10O-70% nuclei
stained) in 19 (25%) tumours and as low (<10% nuclei stained) in 33 (43%) tumours. Twelve (18%) tumours exhibited gene mutation (ten
missense and two nonsense mutations) and an additional five tumours contained changes that could not result in amino acid substitution or
protein truncation. There was no correlation between gene expression and mutation, mutations being equally frequent in tumours with either
high (4/25), intermediate (4/19) or low protein expression (4/33). Fifty-eight patients were eligible for survival analysis. There was a strong
correlation between p53 mutation and cause-specific survival; median survival among mutated cases was 12.5 months compared with >160
months among non-mutated patients (P < 0.005). There was no correlation between p53 overexpression and survival. The results suggest
that p53 mutation status is an important prognostic factor in HNSCC, and that IHC analysis of protein overexpression is an inadequate
measure of gene mutation in these tumours.
Keywords: gene: p53; head and neck neoplasm; carcinoma. squamous cell: polymerase chain reaction - single-strand conformation
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Advances in molecular biologv have provided clues to the patho-
genesis of cancer and show-n the involvement ofoncogene activa-
tion and tumour-suppressor gene inactivation (Chang et al. 1995:
Greenblatt et al. 1994). In the investigation of the carcinogenic
process in head and neck squamous cell carcinoma (HNSCC)
much interest has focused on the p53 tumour-suppressor gene. its
inactivation and the possible prognostic implications ofp53 over-
expression and mutation.
Mutation in the p53 tumour-suppressor gene is the most
frequently found genetic aberration in human cancer (Harris and
Hollstein. 1993). The normal p53 protein functions as a cell cycle
checkpoint and sensor of DNA damage in the cell. and modulates
such important events as G1-arrest. DNA repair and apoptosis
(Levine et al. 1991: Harris and Hollstein. 1993). Cells xwith
mutated p53 are predisposed to further genetic alterations bv
means of inadequate DNA repair. escape from apoptosis and
manifestation ofthe DNA damage in subsequent cell cycles. Other
mechanisms of p53 inactivation include binding to DNA tumour
mirus proteins such as papilloma virus E6. or to overexpressed
cellulargenes such as the MDM2 oncoaene (Lex ine et al. 1994).
The association betmeen head and neck cancer development and
carcinogenic factors such as alcohol or tobacco use. as w-ell as
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exposure to other enxvironmental and occupational factors. is well
documented (Landrinan and Baker. 1991). Several reports reveal
an association between p53 overexpression and p53 mutation in
head and neck carcinogenesis (Field et al. 1991. 1992: Brennan et
al. 1995). Immunohistochemical studies have shown p53 over-
expression to be an early event in HNSCC carcinogenesis. bein,
found in dvsplastic lesions and CIS before the development of
invasixe carcinoma. It is not known if this exent reflects p53
protein accumulation as a result of gene mutation. or merelv a
normal p53 response to DNA damage because of the activity of a
carcinogaen (Bovle et al. 1993: Nees et al. 1993: Pavelic et al.
1994: Shin et al. 1994: Wang et al. 1994: el-Naggar et al. 1995).
Generally an association between mutation and oxerexpression is
assumed. Howxever. in HNSCC there is emerging exidence of a
discrepancy between the results achieved with molecular analx sis
and those usincg immunohistochemical methods (Mineta et al.
1995: Nylander et al. 1995).
The aim of the present inxestigation was txofold: to study the
concordance betx een p53 mutation and immunohistochemical
oxverexpression. and to evaluate the prognostic implications ofp53
mutation/ox erexpression.
MATERIALS
Patients and tumours
The files for the period Januar- 1987 to IMay 1991 in the
Department of Pathology. Unixersity Hospital. Lund. Sxweden.
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were examined and biopsies classified as oral or oropharyngeal
squamous cell carcinoma retrieved and re-examined. Seventy-
seven head and neck cancer specimens were thus identified (Table
1). The corresponding patient charts in the Department of
Otorhinolarvngology/Head & Neck Surgery (tertiarv referral
centre) were reviewed as to the clinical course of disease and the
tumour classification according to UICC criteria (Hermanek and
Sobin. 1987) was reconfirmed. Five tumours were reclassified.
four as hypopharyngeal and one as supraglottic laryngeal. The
male to female ratio was 2.2:1. The initial staging was based on
clinical examination. computerized tomography (CT) or magnetic
resonance (MR) imaging and palpation or endoscopy under anaes-
thesia. Thirty-nine per cent were stage I-II and 61%7c stage III-IV.
Seven patients had recurrent tumours. of the remaining 70 cases.
59% were stage T1-2 and 41% T3-4. 65% were classified NO and
35%c N+. Only two patients had distant metastases at the time of
diagnosis. Thir-t-four per cent of tumours were classified as well
differentiated. 44% as moderately differentiated and 22% as
poorly differentiated.
Treatment
The standard therapy for SCCHN at our department has been
described previously (ZaItterstrom et al. 1991 ) Briefly. the general
principles were as follows: patients with TI tumours underwent
primary surgery: for T2 and resectable T3 and T4 tumours. pre-
operative radiotherapy was gisven. with a target absorbed dose of
50 Gy. or in some cases chemotherapy was administered. followed
by surgery: laryngeal TI-3 carcinomas and all non-resectable T3
and T4 tumours were gilen full-dose radiotherapy (64-70 Gy.) in
some cases followed by salvage surgery. those with regional
metastasis at the time ofdiagnosis were treated with radiotherapy
followed by neck dissection.
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Table 1 Distribution of 77 squamous cell carcinomas with respect to site.
sex, clinical stage, T stage and N stage
Total no. of patients (%)
Site
Tongue 20 26
Oral cavity, other 30 39
Oropharynx 22 29
Hypopharynx/supraglottic larynx 5 6
Stage
10 13
11 20 26
III 15 19
IV 32 42
Primary tumour stage
Ti 10 13
T2 31 40
T3 14 18
T4 15 20
rTi 2 3
rT4 5 7
Nodal status
NO 50 65
Ni 11 14
N2 15 20
N3 1 1
METHODS
Immunohistochemistry
Sections (4 gm thick) %vere dewaxed v-ith xylene. hydrated
through graded alcohols and rehydrated in w-ater. Sections were
heated three times in a micro% a% e oven in citrate buffer (pH 6.0)
: c-a-ce, 7OM P3
Figure 1 SSCP gel. sequencing gel and p53 immunohistochemistry on a tumour from a 70-year-old man with a poorty differentiated carcinoma of the tongue.
The tumour has a G - A mutation in codon 245. exon 7. and intense nuclear p53 staining
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for 5 mmn each time. allowed to cool to the room temperature grad-
ually and finally rinsed in distilled water. Endogrenous peroxidase
activity was blocked using 0.5% hydrogen peroxide in methanol at
room temperature for 30 min. after which sections were rinsed in
distilled water and PBS (phosphate-buffered saline). Twenty per
cent rabbit serum was applied to the sections for 10mn as a
blockina reagyent to reduce non-specific bindingy. A 1:1000 dilution
of the monoclonal antibody to p53 protein (Do7: Dako.
Copenhagen. Denmark). w-hich recognizes both wild-type and
mutant protein was used as the primary antibody. DO-7 recognizes
an epitope in the N-terminus of the human p53 protein residing
between amino acids 35 and 45.
Sections were incubated at 4ZC overmight. After return to room
temperature for 30 mmn. sections were rinsed in PBS and incubated
with the biotinylated secondary antibody for 30 min. followed by
streptavidin peroxidase reagents (StreptABComplex. Dako) for
30 mim. After washing in PBS. sections were incubated in
diaminobenzidine solution for 5 mmn. washed in tap water for
10 iun and then counterstained with Mayer's haematoxylin.
The different pattems of stainin, were scored from 1 to 3: with
less than 10%7 staining nuclei scored 1. 10-70% staining nuclei 2
and more than 70%7c staining nuclei 3.
DNA extraction from the archival material
We extracted DNA from paraffin blocks using the method of
Lungu et al (1992). Briefly. three 10 jm sections were taken from
the paraffin block. placed in a microfuge tube with 150 ji ofdiges-
tion buffer containinc 50 mM Tris (pH 8.5). 1 mMr EDTA. 0.5%
Tween 20 and 200 jg ml-' Proteinase K. Sections were incubated
at 65°C for 2 h. then heated to 95°C for 10 min to destroy the
proteinase. The samples were then centrifuged for S min at full
speed. after which the aqueous phase containing, DNA from the
archival materials was removed and stored at-70'C.
PCR-SSCP
The polymerase chain reaction single-stranded conformation poly-
morphism (PCR-SSCP) analysis was performed using a method
previously described (Orita et al. 1989). Briefly. 80 ng of DNA
was subjected to PCR amplification in a total volume of 30 jl of
reaction mixture containing 10 mM Tris-HCI (pH 8.3). 50 mM
potassium chloride. 1.5 m.i magnesium chloride. 0.5 jim of each
primer. 125 jiM of each deoxyribonucleoside triphosphatase
(dNTP). 0.8 jCi of [a-2P]dCTP (specific activity 3000 Ci
mmol-': Amersham. Bucks. UK). and 0.5 U of Taq Polymerase
(Perkin Elmer. Roche Molecular Systems. Branchburg. NJ. USA).
Thirty-five cycles of denaturation (95°C) for 50 s. annealing
(58°C) for 50 s and extension (72°C) for 70 were carried out using
an automated DNA thermal cycler (Omnigene thermal cycler.
Hybaid. Teddington. UK). Four pairs ofprimers specific for exons
5-8 ofthe p53 gene were used:
exon 5: (SF) 5'TTCCTCVI'CCTGCAGTACTC 3'
(SR) 5' CAGCTGCTCACCATCGCTAT 3'
exon 6: (6F) 5' CACTGATTGCTCT1AGGTCT 3'
(6R) 5' AGTTGCAAACCAGACCTCAG 3'
exon 7: (7F) 5' TCTCCTAGGTTGGCTCTGAC 3'
(7R) 5' CAAGTGGCTCCTGACCTGGA 3'
exon 8: (8F) 5' CCTATCCTGAGTAGTGGTAATC 3'
(8R) 5' CTI-GCCITACCTCGCTIAGTG 3'
Table 2 The relationship between immunohistochemical p53 nuclear
staining and p53 mutation with a change in amino acid sequence or a stop
codon
Immunohistoctemical p53 staining
(<10%) (10-70%) (>70%) n
p53 mutation
Yes 4 4 4 12
No 29 15 21 65
n 33 19 25 77
Table 3 Descripton of p53 gene mutations and variants found in 77
squamfous cell carcinomas of the head and neck
Case Exon Codon Nuckeotde Amino acid IHC
126 5 141 TGC -*TGA Cys to Stop
...
77 5 150 ACA ATA Thrtolle
125a 5 177 CCC TCC ProtoSer
204a 6 192 CAG TAG Gin to Stop
60 6 216 GTG ATG ValtoMet
...
191 7 237 ATG ATC Metto Ile
99 7 241 TCC TGC SertoCys
172 7 245 GGC-AGC Gly to Ser
...
193a 7 245 GGC TGC GlytoCys
205 8 279 GGG TGG GlytoTrp
56 8 281 GAC TAC AsptoTyr
86a 8 290 CGC CTC ArgtoLeu
186 5 142 CCT -CCA Pro to Pro
...
190t 7 248 CGG AGG ArgtoArg
858 7 249 AGG AGA ArgtoArg
73t 8 282 CGGG AGG ArgtoArg
122t 8 282 CGG-AGG Arg to Arg
afXCiJuded from survival analysis because of lack offollow-up. ,Silent variants
excluded from survival analysis. IHC, immunohistochemical staining scores:
<10% nuclei stained: '' 10-70% nuclei stained.
- >700% nuclei stained.
For SSCP aliquots (1-5 gl) of the amplification mixture were
mixed with a sequence stop solution (9-5 gl) (98%c deionized
formamide. 10 m-M EDTA (pH 58.0). 0.025%7c xylencvanol and
0.025% bromophenol blue). heated at 95°C for 5 min and imrnedi-
ately loaded on to a 6% non-denaturing polyacrylamide gel
containing 5% glycerol. Gels were run at 8 W for 13-14 h at room
temperature. wrapped in thin plastic film and autoradiography was
performed for 24-72 h.
DNA sequencing
Positive samples were directly sequenced by the dideoxy chain
termination method using the Sequenase Version 2.0 kit (United
States Biochemical. Cleveland, OH. USA). following the isolation
of single-stranded DNA by means of Dynabeads M-280
Streptavidin (Dynal. Oslo. Norway). Briefly. using oligonu-
cleotide primers biotinylated at the 5'-end of the coding strand.
PCR amplification was performed with 160 ng of genomic DNA.
The conditions of amplification w-ere the same as those for PCR-
SSCP except for omitting a-'PdCTP and using biotinylated
primers. An aliquot of 25 gl of the PCR mixture was used to
isolate single-stranded DNA. accordin, to the manufacturer's
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Table 4 Distribution of mutation with respect to T stage. N stage and clinical
stage in 58 HNSCCS evaluated for survival
p53 mutation No mutation
(n=8) (n= 50)
Ti 1 9
T2 5 21
T3 1 11
T4 1 9
NO 4 35
N+ 4 15
Stage HlI 3 21
Stage 11-4V 5 29
directions. The samples were electrophoresed through 4.5%7 poly-
acrylamide gel containing 8.3 xi urea for 1-2 h at 45 W. and the
subsequently dried gel was exposed to KodakX-AR (Eastman
Kodak Company. Rochester. NY) film for 48-72 h. Primers used
were as follows:
exon 5: (5F) 5' biotin-TTCAACTCTGTCTCCTTCCT 3'
(SR) 5' GCAATCAGTGAGGAATCAGA 3'
sequencing pnmer:
5' CAGCCCTGTCGTCTCCAG 3'
exon 6: (6F) biotinylated primer. the same as for exon 5
(6R) 5' CGGAGGGCCACTGACAACCA 3'
sequencing pnmer:
5' TTAACCCCTCCTCCCAGAGA 3'
exon 7: (7F) 5' biotin-AGGCGCACTGGCCTCATCTT 3'
(7R) 5' AGGGGTCAGCGGCAAGCAGA 3'
sequencingy primer:
5' TGTGCAGGGTGGCAAGTGGC 3'
exon 8: (8F) 5' biotin-TTGGGAGTAGATGGAGCCT 3'
(8R) 5' AGTGTTAGACTGGAAACTTT 3'
sequencing, pnmer:
5' AGGCATAACTGCACCCTYI7GG 3'
Survival analysis
AH medical records were reviewed for sunrixal analysis. Patients
with previous malignancies. recurrent tumours. treatment other
than for cure or death within 3 months after diagnosis were
excluded. This left 58 evaluable cases. Follow-up. performed on
an ambulant basis after completed therapy. extended to 30 August.
1995. Patients were thus followed for at least 9 months or until
death. Median duration offollow-up was 39.2 months (mean 45.3
months: range 3.6-90.7 months). Onlv six patients were followed
less than 2 years.
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Figure 2 Kapln-Meier survival curve with respect to cancer death only for
the groups with and without mutations as determined by conformational
changes of p53 (n = 58; P< 0.005)
Statistical methods
Statistical analysis w-as performed with SPSS (Statistical Package
for the Social Sciences) 6.1 (SPSS. Chicago. IIL. USA). The
Kaplan-Meier method was used for plotting survival curnes. Log-
rank test was used for survival analysis. Multivariate analysis
(Cox's proportional hazards model) was used to test whether the
differences were confounded bv other host or tumour factors.
Possible differences in the distribution of those factors between
the different groups were investigated using the chi-square test.
Fisher's exact test or Student's t-test. P-values quoted were two-
tailed and were considered statistically significant when less than
0.05.
RESULTS
The cancer samples generally had little stromal cell contamination
and only a few samples contained a minor fraction oftumour cells.
In general. two-thirds or more of the slides consisted of tumour
cells. Onlv 3 out of the 77 biopsy specimens studied were consid-
ered to haxe scant tumour. The first had no detectable p53
mutation and high (>70%c) nuclear staining. The second had no
detectable p53 mutation. and less than 10% nuclear staining. The
third had a p53 mutation and less than 10% nuclear staining. Only
the second patient was eligible for survixval analysis (treated for
cure. no previous malignancy).
Immunohistochemistry
Fomr-four cases (57.1%) of the 77 analysed tumours revealed
immunohistochemical positivity for p53 (> 10% staining nuclei).
Table 5 Mulftivariate analysis of risk factors in 58 HNSCCs evaluated for cause-specific survival
Variable Relative risk 95% confidence interval Significancelevel
NO vs N+ 2.57 0.85-7.84 0.0960
T-stage 1-4 1.72 0.50-5.95 0.3895
Clinical stage HV 1.20 0.28-5.25 0.8052
Age 0.74 0.29-1.85 0.5159
p53 mutation 9.87 3.21-30.34 0.0001
British Joumal ofCancer (1998) 78(8), 1084-1090 0 CancerResearch Campaign 19981088 HMineta etal
1.0.
a
a a
E
0
0.8 -
0.6
0.4 q
02 -
u0.
0 20 40 60
Trne afterdiagns (mont
Fjgure 3 Kapban-Mee survival curve with respect to
the groups with low (<10°% staining nuclei), intermedat
nucleoi) and high (>70% staining nuclei) p53 expression
staining (10-70%) and 26% high staining (>70%). Neither for p53
mutation (missense. nonsense and silent) nor for p53 immunohisto-
chemical overexpression (data not shown) were there any differ-
10-70%no (n = 15) ences in the distribution ofT or N status. stage. age or sex between
the groups (Table 4).
<10% (n =28) Univariate analysis revealed both N status (P = 0.01. log rank)
and p53 mutation (P = 0.001. log rank) (Figure 2) to be associated
with survival. This was. however. not the case for immunohisto-
chemical expression of p53 (Figure 3). Median survival for
>70% (n = 15) patients with missense or nonsense p53 mutation was 12.5 months
and for patients without such mutations median survival extended
beyond 90 months. In a furthersubgroup. survival analysis ofp53- 80 10 ~ mutated and non-mutated cases was subdivided into groups with
or without increased immunohistochemical p53 expression.
ly death for Whether or not the cut-off limit was between <10% and > 10%
(10-70% staining staining nuclei. or between <70% and >70% staining nuclei (data
(n= 58; P= NS) not shown), no further prognostic information was gained. Using
this subdivision some ofthe groups, however, were small.
In a multivariate analysis, p53 mutation was still a strong risk
Among them 25 cases were scored 3 (more than 70% staining
nuclei) and 19 cases were scored 2 (between 10% and 70%
staining nuclei). Thirty-three cases (42.9%) showed score 1 (less
than 10% staining nuclei) (Table 2).
p53 mutations
Nucleotide sequence alterations were found in 17 (22%) ofthe 77
analysed tumours. Ten ofthese were missense mutations resulting
in amino acid substitutions. two were nonsense mutations resulting
in protein truncation, whereas five alterations would not lead to
amino acid changes (Table 3). Thus, only 12 (16% of77) tumours
exhibited mutations that could alter the function of the protein.
Seven ofthese were transversion mutations (four G -e T. one C -e
A. one C -* G. one G -* G). and five were transitions (two G -* A
and three C -e T. none at CpG dinucleotides). In the following
computations. only cases exhibiting missense or nonsense muta-
tion were included.
PCR-SSCP vs IHC analysis
The concordance between p53 mutation, resulting in a missense or
nonsense mutation, and increased p53 expression in immunohisto-
chemistry was poor(Table 2). Ifonly cases with eitherhigh or low
IHC expression (n = 58) are considered, IHC and PCR-SSCP
analysis were discordant in 25 cases (43%). A SSCP gel,
sequencing gel and immunohistochemistry staining of a tumour
with concordant findings are shown in Figure 1.
Among 33 cases with no p53 expression immunohistochemi-
cally, four cases (12.1%) demonstrated mutations and 29 cases
(87.9%) did not. Four (21.1%) out of 19 cases scoring 2 immuno-
histochemically had mutations. and four cases (16.0%) out of 25
cases scoring 3 had mutations. This result did not reveal any
significant correlation between p53 mutation and p53 overexpres-
sion (Table 2).
Survival vs p53 mutation/overexpression
Eight of 58 evaluable cases exhibited a p53 mutation resulting in a
missense ornonsense mutation (Table 3). Ofthese 58 tumours. 48%
exhibited low p53 IHC (<10% staining nuclei). 26% intermediate
tactor and the impact ot N status was reduced below sigmticance
(Table 5).
DISCUSSION
p53 mutations that lead to altered protein conformation can make
the protein more stable and prolong its half-life (Lane and
Benchimol. 1990). It is therefore possible to detect an accumulation
of mutated p53 protein in head and neck cancer using immuno-
histochemistry. The frequency of p53 immunohistochemical over-
expression in the present material (57% with > 10% staining nuclei)
is in accordance with findings in previous studies ofHNSCC (Field
et al. 1991, 1993: Ogden et al. 1992: Watling et al. 1992: Dowell
and Hall. 1994: Xu et al, 1994: Nylander et al. 1995).
As we previously reported in preliminary form (Mineta et al.
1995). there is a pronounced discordance between p53 mutation
and p53 immunohistochemical overexpression. This confinns
some earlier findings in HNSCC (Xu et al. 1994; Nylander et al.
1995) and in skin cancers (Kubo et al, 1994). butcontradicts others
(Ahomadegbe et al, 1995). The difference in findings is not likely
to be attributed to the antibody used as DO-7 was applied in the
present as well as in two (Ahomadegbe et al. 1995: Nylander et al.
1995) ofthe four other studies.
False-negative findings (mutation without overexpression) can
be attributed to p53 mutations at splice sites, frame shifts or
nonsense mutations, which would be predicted to encode for trun-
cated p53 proteins not detected by iinmmmunohistochemistry.
Studies ofthe crystal structure ofthe p53 tumour suppressor-DNA
complex (Cho et al, 1994; Milner, 1995) have made it clearthat the
majority ofp53 point mutations affect the residues within the core
domain and inactivate the function by abolishing its sequence-
specific DNA-binding capacity. However, these mutations do not
significantly affect the structure ofthe protein.
Therefore, the discrepancy between the PCR-SSCP and the
immunohistochemical results may depend on the site ofp53 muta-
tion or the anti-p53 antibody employed. Negative staining may
also be due to overfixation. delayed fixation or inadequate tissue
processing of the tumour sample, which allows degradation of the
p53 protein.
The p53 antibody (Do-7) used in this study reacts with both the
wild type and mutant type of the p53 protein. Our data, which
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demonstrate three cases with p53 missense mutations not detected
immnunohistochemicallv. suggest that the mutational change in the
p53 gene does not necessarily result in increased stability of the
p53 protein.
Discordant results (i.e. nuclear staining without pS3 mutation)
can depend on the sequencing strategy. For example. mutations
may occur outside the studied exons 5. 6. 7 and 8. For HNSCC.
however. approximately 98%e of mutations are found w-ithin exons
5-8 (Greenblatt et al. 1994). Other reasons for the failure ofdetec-
tion of p53 mutations include insufficient tumour in the sample or
insufficient quality ofDNA from archival materials.
Overexpression is not only seen in gene mutation. but also in
cases with retention of the wild-type target protein in the tumour
cell. Both mutational stabilization of the p53 protein and elevated
levels of wild-type p53 protein allow detection by immunohisto-
chemistry. Thus. if the secondary stabilization of p53 occurs by
some mechanism other than gene mutation. overexpression can be
demonstrated.
Accumulation of wild-type p53 protein has been found in an
inherited cancer (Barnes et al. 1992) or cancer treated w-ith
chemotherapeutic drugs or radiation (Kastan et al. 1991:
Vogelstein and Kinzler. 1992).
Such non-mutational stabilization of the protein is most prob-
ably the result of interruption of the normal degradative pathway
of p53. Other proteins such as the products of cellular oncogene
mdm-2 (Monaud et al. 1992: Meltzer. 1994). or the products of
DNA v-iruses. including SV-40 large T antigen. Elb of adenovirus
(Gannon et al. 1990: Cesarman et al. 1993) and E6 of HPV
(Scheffner et al. 1990: Wemess et al. 1990) can bind to the p53
gene and inacti-ate the abilitv to act as a transcription factor.
resulting in p53 stabilization. Phosphorylation due to cdc2-like
kinase could also alter the p53 protein. which can then be detected
bv immunohistochemistrv (Moll et al. 1992).
In the present study p53 mutations were found at a frequency of
16%c (12177). which is within the lower range of the percentage of
abnormal findings reported in the literature in HNSCC (Boyle et
al. 1993: Brennan et al. 1995: Dowell and Hall. 1994: Greenblatt
et al. 1994: Xu et al. 1994: Nvlander et al. 1995). The low
frequency may reflect the small sample size currentlv available. or
it mav be due to inconsistent amplification of DNA from archi-al
materials. or to lower mutated DNA concentration in samples.
although mutations are reported to be still detectable when consti-
tuting only 15%7c oftotal DNA (Wu and Darras. 1993).
The issue of decreased sensitivitv caused by contaminatinc,
benign cells is of greatest importance in PCR studies involving
detection ofloss ofheterozygositv. for example. In studies such as
ours. it is unclear how much contaminating cells lower the
threshold of detection ofp53 mutation in formalin-fixed material.
if at all. and a samplejudged insufficient in the amount of tumour
for immunohistochemical assessment produced evidence of p53
mutation in the PCR. The proportion oftumour cells in all samples
vastly exceeded. in any case. the generally accepted sensitivity of
PCR in detecting 1 mutated cell amongy 100 000 normal cells.
The simple possibility that a dissimilarity exists between
cohorts ofpatients with respect to carcinogen exposure may influ-
ence the findings. It also appears as though the frequency of
detected mutations max be lower when DNA is retrieved from
archival rather than from fresh tissue.
Studies have implicated p53 protein expression as an indepen-
dent prognostic factor in carcinomas of the breast. stomach.
colonlrectum, bladder and NSCLC [review-ed in Changa et al
(1995). Dowell and Hall (1994)]. The clinical relevance of p53
overexpression in HNSCC has been under debate. We could not
find any correlation between p53 immunohistochemical overex-
pression and survival (Figure 3). There are studies indicatinc a
correlation between p53 overexpression and survival. some
reporting better survival in patients wvith overexpression (Sauter et
al. 1992). Overexpression has also been reported to show strong
association with a histoloaical malignancy grading scale with
prognostic capability (Watling et al. 1992). However. the lack of
correlation betmeen p53 expression and clinicopathological para-
meters or survival as originally reported by Field et al (1991) has
subsequently been substantiated by many reports [reviewed in
Field et al (1993)].
Studies on the relation betmeen p53 mutation in HNSCC and
clinicopathological parameters or survival are sparse. Koch et al
(1996) found an association with recurrence but not survival. The
present finding ofp53 mutation as a strong and independent prog-
nostic variable contrasts with the results of Ahomadeabe et al
(1995). who did not find any correlation between mutation and
clinical staae or 5-year survival. However. they studied fresh
tissue from both metastases (n = 50) andprimary tumours (n =28).
13 of which were matched specimens. They also found a good
correlation between mutation and overexpression. Nvlander et al
(1995) in a studv of 80 HNSCCs of the oral cavity using archival
specimens could not find any relation between p53 mutation and
survival. Their material. however. deviated from the general char-
acteristics of HNSCC. w-ith a male to female ratio of 0.86:1 and a
high frequency of a novel non-random 14-bp deletion in exon 8
(Nylander et al. 1996). differences that might explain the
discordant findings w-ith respect to survival.
In conclusion. we verified previous findings ofa lack ofconcor-
dance between immunohistochemical overexpression of nuclear
p53 and mutation of the p53 gene. as well as the absence of prog-
nostic information with respect to survival in p53 overexpression.
On the other hand. p53 mutation seems to be a strong and indepen-
dent variable for survival prognosis.
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